All companies › MLYS

MLYS · Mineralys Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells3
Research cases0
Last filing2026-09-30

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-21 — Warren Eric · sold 7,438 @ $28.12 2026-09-22 — Slingsby Brian Taylor · sold 104,320 @ $28.81 2026-09-30 — Congleton Jon · sold 75,000 @ $25.46
2026-09-212026-09-30

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Warren Eric Chief Commercial Officer
Slingsby Brian Taylor Director
Congleton Jon Chief Executive Officer, Director
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $MLYS is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-30', 'insider_name': 'Congleton Jon', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 75000.0, 'price': 25.4622, 'value': 1909665.0, 'is_buy': False}, {'transaction_date': '2026-09-22', 'insider_name': 'Slingsby Brian Taylor', 'insider_title': 'Director', 'transaction_type': 'Open-market sell', 'shares': 104320.0, 'price': 28.81, 'value': 3005459.2, 'is_buy': False}, {'transaction_date': '2026-09-21', 'insider_name': 'Warren Eric', 'insider_title': 'Chief Commercial Officer', 'transaction_type': 'Open-market sell', 'shares': 7438.0, 'price': 28.12, 'value': 209156.56, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for MLYS today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.